Skip to main
HROW

HROW Stock Forecast & Price Target

HROW Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 86%
Buy 14%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Harrow is a profitable biotechnology company focused on delivering a broad slate of best-in-class eye-care products to the US market. With a portfolio of 18 branded ophthalmic pharmaceuticals and a strong focus on commercialization and acquisition, the company is well-positioned for growth. The recent hiring of a sales force specifically targeting the drug VEVYE, along with upcoming clinical data for IHEEZO in the intravitreal injection space, are expected to be key catalysts for future growth. With a strong management team and a clear focus on driving sales, Harrow appears poised for continued success.

Bears say

Harrow is facing several fundamental challenges that may hinder its growth and profitability. One of the main concerns is its reliance on the MELT franchise, which is not included in its latest guidance. The company's history of operating losses, regulatory risks, potential need for additional funding, and intense competition also contribute to a negative outlook. Additionally, the success of its assets, such as Iheezo and QUELL, is integral to its future profitability and any delays or difficulties in their adoption could significantly impact Harrow's valuation.

HROW has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 86% of analysts recommend a Strong Buy, 14% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Harrow Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Harrow Health Inc (HROW) Forecast

Analysts have given HROW a Strong Buy based on their latest research and market trends.

According to 7 analysts, HROW has a Strong Buy consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $69.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $69.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Harrow Health Inc (HROW)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.